Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F21%3A43920191" target="_blank" >RIV/00216208:11120/21:43920191 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1111/bjd.19262" target="_blank" >https://doi.org/10.1111/bjd.19262</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/bjd.19262" target="_blank" >10.1111/bjd.19262</a>
Alternative languages
Result language
angličtina
Original language name
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study
Original language description
BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralises interleukin-17A, a cornerstone cytokine in psoriasis, has shown long-lasting efficacy and safety in the complete spectrum of psoriasis manifestations. OBJECTIVE: To report the long-term (2.5-year) efficacy and safety of secukinumab in nail psoriasis. METHODS: TRANSFIGURE, a double-blind, randomised, placebo-controlled, parallel-group, multicentre Phase 3b study in 198 patients, investigated secukinumab 150 and 300 mg in moderate to severe nail psoriasis patients. RESULTS: At Week 16, the primary endpoint NAil Psoriasis Severity Index (NAPSI) was met, demonstrating superiority of secukinumab to placebo. The effect was sustained over 2.5 years with a large benefit on nail clearance with mean NAPSI improvement of -73.3% and -63.6% with secukinumab 300 and 150 mg, respectively. At 2.5 years, secukinumab demonstrated sustained clinically significant reductions in total mean Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) QoL scores by -52.4% and -18.1%, and 70.2% and 70.9% of patients achieved a weighted NAPPA-PBI (Patient Benefit Index) global score of GREATER-THAN OR EQUAL TO2 with secukinumab 300 and 150 mg, respectively. Patients showed considerable improvements in Euro-QoL 5-Dimension Health Status Questionnaire at 2.5 years, reporting decreased pain and discomfort. No new safety findings were observed. CONCLUSIONS: Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2.5 years in nail psoriasis, with significant sustained QoL improvements and a favourable safety profile.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30216 - Dermatology and venereal diseases
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
British Journal of Dermatology
ISSN
0007-0963
e-ISSN
—
Volume of the periodical
184
Issue of the periodical within the volume
3
Country of publishing house
GB - UNITED KINGDOM
Number of pages
12
Pages from-to
425-436
UT code for WoS article
000599066000001
EID of the result in the Scopus database
2-s2.0-85097133895